Adjusted EBITDA increased 7.3% at constant currency to CHF 440 million.

For the full fiscal year 2022, reported net sales were $12.44 billion, showing an increase of 7% compared to the prior year period. On a comparable basis, currency-neutral sales increased by 9%, with growth achieved across all divisions, led by double-digit increases in Nourish and Pharma.